Pseudomonas aeruginosa is not just in the intensive care unit any more: Implications for empirical therapy

Critical Care Medicine

Volumn 40, Issue 4, 2012, Pages 1329-1332

  Eagye, Kathryn J ^a   Banevicius, Mary A ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

antibiotic resistance; ICU; P. aeruginosa; pharmacodynamics; surveillance

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; UNITED STATES;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED STATES;

EID: 84858772073     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31823bc8d0     Document Type: Article

References (10)

1. Albrecht SJ, Fishman NO, Kitchen J, et al: Reemergence of Gram-negative health care-associated bloodstream infections. Arch Intern Med 2006; 166:1289-1294
2. Eagye KJ, Kim A, Laohavaleeson S, et al: Surgical site infections: Does inadequate antibiotic therapy affect patient outcomes? Surg Infect (Larchmt) 2009; 10:323-331
3. Eagye KJ, Kuti JL, Sutherland CA, et al: In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty U. S. hospitals. Clin Ther 2009; 31:2678-2688
4. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. CLSI document M100-S19 (ISBN 1-56238-690-5). Wayne, PA, CLSI, 2009
5. DeRyke CA, Kuti JL, Nicolau DP: Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007; 27:333-342
6. Turnidge JD: The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27:10-22
7. Crandon JL, Bulik CC, Kuti JL, et al: Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 1111-1116
8. Wright DH, Brown GH, Peterson ML, et al: Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46:669-683
9. Drusano GL, Preston SL, Fowler C, et al: Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189:1590-1597
10. Doshi RK, Patel G, Mackay R, et al: Healthcare-associated infections: Epidemiology, prevention, and therapy. Mt Sinai J Med 2009; 76:84-94